<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39555399</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>Long-term effectiveness of an ultra-rapid rollout vaccination campaign with BNT162b2 on the incidence of SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>111117</StartPage><MedlinePgn>111117</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">111117</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2024.111117</ELocationID><Abstract><AbstractText>In 2021, an ultra-rapid rollout vaccination campaign in the Schwaz district, Tyrol, Austria, delivered the COVID-19 vaccine BNT162b2 to 66.9% of eligible residents (dose 1: March 11-16, dose 2: April 8-13). Alongside the campaign, we recruited 11,955 residents into the prospective study REDUCE, of whom 3,859 participated in a booster vaccination initiative (November 20-28, 2021). Over a 24-month follow-up, 1,672 participants had incident RT-PCR-confirmed SARS-CoV-2. Compared to other Tyrolean districts, effectiveness in reducing SARS-CoV-2 infection at months 1-9 versus months 10-24 was 81.6% (95% CI 80.0-83.2%; hazard ratio 0.18 [0.17-0.20]) versus 38.2% (35.8-40.6%; 0.62 [0.59-0.64]) among REDUCE participants, and 22.5% (20.5-24.4%; 0.78 [0.76-0.80]) versus 17.0% (16.2-17.8%; 0.83 [0.82-0.84]) in the entire Schwaz district, with substantial variability during follow-up. By March 2023, 61% of Schwaz residents had received booster vaccination versus 55% in other Tyrolean districts. Consequently, vaccinating individuals at high pace effectively reduced SARS-CoV-2 infections and achieved higher vaccination coverage.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tschiderer</LastName><ForeName>Lena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Innerhofer</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seekircher</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waltle</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, 1220 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimpel</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Virology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lass-Flörl</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forer</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schönherr</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Public Health, Syracuse University, Syracuse, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krammer</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Embacher-Aichhorn</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Trial Center, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilg</LastName><ForeName>Herbert</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Günter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine II, Infectious Diseases, Immunology, Pneumology and Rheumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allerberger</LastName><ForeName>Franz</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Infectious Disease Epidemiology, Austrian Agency for Health and Food Safety, 1220 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willeit</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Health sciences</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Virology</Keyword></KeywordList><CoiStatement>P.W. reports consulting fees from Novartis Pharmaceuticals; outside the submitted work. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list F.K. as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, CastleVax, to develop SARS-CoV-2 vaccines. F.K.is co-founder and scientific advisory board member of CastleVax. F.K. has consulted for Merck, Curevac, Seqirus, and Pfizer and is currently consulting for 3rd Rock Ventures, GSK, Gritstone, and Avimex. The Krammer laboratory is collaborating with Dynavax on influenza vaccine development.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39555399</ArticleId><ArticleId IdType="pmc">PMC11567098</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2024.111117</ArticleId><ArticleId IdType="pii">S2589-0042(24)02342-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 2023. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic</Citation></Reference><Reference><Citation>Mathieu E., Ritchie H., Rodés-Guirao L., Appel C., Giattino C., Hasell J., Macdonald B., Dattani S., Beltekian D., Ortiz-Ospina E., et al.  Coronavirus Pandemic (COVID-19) 2020. https://ourworldindata.org/coronavirus</Citation></Reference><Reference><Citation>Seekircher L., Siller A., Astl M., Tschiderer L., Wachter G.A., Pfeifer B., Huber A., Gaber M., Schennach H., Willeit P. Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022. Viruses. 2022;14:1877. doi: 10.3390/v14091877.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091877</ArticleId><ArticleId IdType="pmc">PMC9502884</ArticleId><ArticleId IdType="pubmed">36146684</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Moreira E.D., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Polack F.P., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021;385:1761–1773. doi: 10.1056/NEJMoa2110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegale F., Manica M., Zardini A., Guzzetta G., Marziano V., d'Andrea V., Trentini F., Ajelli M., Poletti P., Merler S. Evaluation of Waning of SARS-CoV-2 Vaccine-Induced Immunity: A Systematic Review and Meta-analysis. JAMA Netw. Open. 2023;6 doi: 10.1001/jamanetworkopen.2023.10650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.10650</ArticleId><ArticleId IdType="pmc">PMC10157431</ArticleId><ArticleId IdType="pubmed">37133863</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Puzniak L., Hong V., Frankland T.B., Xie F., Ackerson B.K., Valluri S.R., Jodar L., McLaughlin J.M. Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study. Lancet Respir. Med. 2023;11:176–187. doi: 10.1016/S2213-2600(22)00354-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00354-X</ArticleId><ArticleId IdType="pmc">PMC9765328</ArticleId><ArticleId IdType="pubmed">36216013</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira E.D., Kitchin N., Xu X., Dychter S.S., Lockhart S., Gurtman A., Perez J.L., Zerbini C., Dever M.E., Jennings T.W., et al. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N. Engl. J. Med. 2022;386:1910–1921. doi: 10.1056/NEJMoa2200674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200674</ArticleId><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu N., Joyal-Desmarais K., Ribeiro P.A.B., Vieira A.M., Stojanovic J., Sanuade C., Yip D., Bacon S.L. Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir. Med. 2023;11:439–452. doi: 10.1016/S2213-2600(23)00015-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00015-2</ArticleId><ArticleId IdType="pmc">PMC9917454</ArticleId><ArticleId IdType="pubmed">36780914</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H.H., Tang P., Coyle P., Yassine H.M., Al Thani A.A., Al-Khatib H.A., Hasan M.R., Al-Kanaani Z., Al-Kuwari E., et al. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect. Dis. 2023;23:816–827. doi: 10.1016/S1473-3099(23)00058-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00058-0</ArticleId><ArticleId IdType="pmc">PMC10079373</ArticleId><ArticleId IdType="pubmed">36913963</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso A., Flacco M.E., Soldato G., Di Martino G., Acuti Martellucci C., Carota R., De Benedictis M., Di Marco G., Di Luzio R., Fiore M., et al. COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follow-Up. Vaccines (Basel) 2023;11 doi: 10.3390/vaccines11081325.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11081325</ArticleId><ArticleId IdType="pmc">PMC10459219</ArticleId><ArticleId IdType="pubmed">37631893</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas E.J., Angulo F.J., McLaughlin J.M., Anis E., Singer S.R., Khan F., Brooks N., Smaja M., Mircus G., Pan K., et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397:1819–1829. doi: 10.1016/S0140-6736(21)00947-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00947-8</ArticleId><ArticleId IdType="pmc">PMC8099315</ArticleId><ArticleId IdType="pubmed">33964222</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchia A., Ferrante D., Angeleri P., Biscayart C., Mariani J., Esteban S., Tablado M.R., de Quirós F.G.B. Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country. JAMA Netw. Open. 2021;4 doi: 10.1001/jamanetworkopen.2021.30800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30800</ArticleId><ArticleId IdType="pmc">PMC8556631</ArticleId><ArticleId IdType="pubmed">34714342</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas E.J., McLaughlin J.M., Khan F., Angulo F.J., Anis E., Lipsitch M., Singer S.R., Mircus G., Brooks N., Smaja M., et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect. Dis. 2022;22:357–366. doi: 10.1016/S1473-3099(21)00566-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00566-1</ArticleId><ArticleId IdType="pmc">PMC8457761</ArticleId><ArticleId IdType="pubmed">34562375</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos C.V.B.D., Noronha T.G.d., Werneck G.L., Struchiner C.J., Villela D.A.M. Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: A retrospective observational study. Lancet Reg. Health. Am. 2023;17 doi: 10.1016/j.lana.2022.100418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100418</ArticleId><ArticleId IdType="pmc">PMC9779315</ArticleId><ArticleId IdType="pubmed">36575682</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschiderer L., Seekircher L., Richter L., von Laer D., Lass-Flörl C., Forer L., Schönherr S., Krammer F., Embacher-Aichhorn S., Tilg H., et al. Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population. iScience. 2022;25 doi: 10.1016/j.isci.2022.105380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.105380</ArticleId><ArticleId IdType="pmc">PMC9639213</ArticleId><ArticleId IdType="pubmed">36373097</ArticleId></ArticleIdList></Reference><Reference><Citation>Braeye T., van Loenhout J.A.F., Brondeel R., Stouten V., Hubin P., Billuart M., Chung P.Y.J., Vandromme M., Wyndham-Thomas C., Blot K., Catteau L. COVID-19 vaccine effectiveness against symptomatic infection and hospitalisation in Belgium, July 2021 to May 2022. Euro Surveill. 2023;28 doi: 10.2807/1560-7917.ES.2023.28.26.2200768.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.26.2200768</ArticleId><ArticleId IdType="pmc">PMC10311948</ArticleId><ArticleId IdType="pubmed">37382885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiuzzi C., Lippi G. Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign. Eur. J. Public Health. 2022;32:328–330. doi: 10.1093/eurpub/ckab220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurpub/ckab220</ArticleId><ArticleId IdType="pmc">PMC8755380</ArticleId><ArticleId IdType="pubmed">34978571</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa R.G., Falavigna M., Manfio J.L., de Araujo C.L.P., Cohen M., do Valle Barbosa G.R.G., de Souza A.P., Romeiro Silva F.K., Sganzerla D., Da Silva M.M.D., et al. BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study. Vaccine. 2023;41:5461–5468. doi: 10.1016/j.vaccine.2023.07.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.038</ArticleId><ArticleId IdType="pubmed">37507274</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullahi Y.A.M. COVID-19 Mass Vaccination Campaign: An International Comparison of Qatar With GCC Nations and Other Global Groups. Int. J. Public Health. 2023;68 doi: 10.3389/ijph.2023.1605614.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/ijph.2023.1605614</ArticleId><ArticleId IdType="pmc">PMC10150879</ArticleId><ArticleId IdType="pubmed">37139243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira L.S., Darcie Marquitti F.M., Paixão da Silva R.L., Borges M.E., Ferreira da Costa Gomes M., Cruz O.G., Kraenkel R.A., Coutinho R.M., Prado P.I., Bastos L.S. Estimating the impact of implementation and timing of the COVID-19 vaccination programme in Brazil: a counterfactual analysis. Lancet Reg. Health. Am. 2023;17 doi: 10.1016/j.lana.2022.100397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100397</ArticleId><ArticleId IdType="pmc">PMC9676113</ArticleId><ArticleId IdType="pubmed">36439909</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Kalkstein N., Mizrahi B., Alroy-Preis S., Ash N., Milo R., Huppert A. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N. Engl. J. Med. 2021;385:1393–1400. doi: 10.1056/NEJMoa2114255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114255</ArticleId><ArticleId IdType="pmc">PMC8461568</ArticleId><ArticleId IdType="pubmed">34525275</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavish N., Yaari R., Huppert A., Katriel G. Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence. Sci. Transl. Med. 2022;14 doi: 10.1126/scitranslmed.abn9836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn9836</ArticleId><ArticleId IdType="pmc">PMC9012104</ArticleId><ArticleId IdType="pubmed">35412326</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y., Zhang W.-B., Wu X., Ruktanonchai C.W., Liu H., Wang J., Song Y., Liu M., Yan W., Yang J., et al. Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories. Nat. Commun. 2022;13:3106. doi: 10.1038/s41467-022-30897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30897-1</ArticleId><ArticleId IdType="pmc">PMC9166696</ArticleId><ArticleId IdType="pubmed">35661759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiemken T.L., Khan F., Puzniak L., Yang W., Simmering J., Polgreen P., Nguyen J.L., Jodar L., McLaughlin J.M. Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe. Sci. Rep. 2023;13:3886. doi: 10.1038/s41598-023-31057-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-31057-1</ArticleId><ArticleId IdType="pmc">PMC9994397</ArticleId><ArticleId IdType="pubmed">36890264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilboa M., Regev-Yochay G., Mandelboim M., Indenbaum V., Asraf K., Fluss R., Amit S., Mendelson E., Doolman R., Afek A., et al. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. JAMA Netw. Open. 2022;5 doi: 10.1001/jamanetworkopen.2022.31778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.31778</ArticleId><ArticleId IdType="pmc">PMC9478782</ArticleId><ArticleId IdType="pubmed">36107426</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedroogh S., Schmiedl S., Thürmann P.A., Graf K., Appelbaum S., Koß R., Theis C., Zia Z., Tebbenjohanns J., Thal S.C., Dedroogh M. Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults. Sci. Rep. 2023;13:9036. doi: 10.1038/s41598-023-34961-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-34961-8</ArticleId><ArticleId IdType="pmc">PMC10239043</ArticleId><ArticleId IdType="pubmed">37270632</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemet I., Kliker L., Lustig Y., Zuckerman N., Erster O., Cohen C., Kreiss Y., Alroy-Preis S., Regev-Yochay G., Mendelson E., Mandelboim M. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N. Engl. J. Med. 2022;386:492–494. doi: 10.1056/NEJMc2119358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2119358</ArticleId><ArticleId IdType="pmc">PMC8823651</ArticleId><ArticleId IdType="pubmed">34965337</ArticleId></ArticleIdList></Reference><Reference><Citation>Siller A., Seekircher L., Astl M., Tschiderer L., Wachter G.A., Penz J., Pfeifer B., Huber A., Gaber M., Schennach H., Willeit P. Anti-SARS-CoV-2 IgG Seroprevalence in Tyrol, Austria, among 28,768 Blood Donors between May 2022 and March 2023. Vaccines (Basel) 2024;12 doi: 10.3390/vaccines12030284.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12030284</ArticleId><ArticleId IdType="pmc">PMC10976183</ArticleId><ArticleId IdType="pubmed">38543918</ArticleId></ArticleIdList></Reference><Reference><Citation>Seekircher L., Astl M., Tschiderer L., Wachter G.A., Penz J., Pfeifer B., Huber A., Afonso P.M., Gaber M., Schennach H., et al. Anti-Spike IgG antibodies as correlates of protection against SARS-CoV-2 infection in the pre-Omicron and Omicron era. J. Med. Virol. 2024;96 doi: 10.1002/jmv.29839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29839</ArticleId><ArticleId IdType="pubmed">39105391</ArticleId></ArticleIdList></Reference><Reference><Citation>GmbH  . Österreichische Agentur für Gesundheit und Ernährungssicherheit. Gesundheit für Mensch, Tier &amp; Pflanze: Coronavirus; 2022. https://www.ages.at/mensch/krankheit/krankheitserreger-von-a-bis-z/coronavirus</Citation></Reference><Reference><Citation>GmbH  . Österreichische Agentur für Gesundheit und Ernährungssicherheit. Gesundheit für Mensch, Tier &amp; Pflanze: Coronavirus; 2023. https://www.ages.at/mensch/krankheit/krankheitserreger-von-a-bis-z/coronavirus</Citation></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Al Thani A.A., Coyle P., Al-Kanaani Z., et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine. 2023;95 doi: 10.1016/j.ebiom.2023.104734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104734</ArticleId><ArticleId IdType="pmc">PMC10404859</ArticleId><ArticleId IdType="pubmed">37515986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V.J., Insalata F., Foulkes S., Kirwan P., Sparkes D., Atti A., Cole M., de Lacy E., Price L., Corrigan D., et al. Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022. J. Infect. 2024;88:30–40. doi: 10.1016/j.jinf.2023.10.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.10.022</ArticleId><ArticleId IdType="pubmed">37926119</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunholtz D.A., Edwards S.J., Lilford R.J. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". J. Clin. Epidemiol. 2001;54:217–224. doi: 10.1016/S0895-4356(00)00305-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(00)00305-X</ArticleId><ArticleId IdType="pubmed">11223318</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R., Sergienko R., Friger M., Peretz A., Beckenstein T., Yaron S., Netzer D., Hammerman A. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat. Med. 2022;28:1486–1490. doi: 10.1038/s41591-022-01832-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01832-0</ArticleId><ArticleId IdType="pubmed">35468276</ArticleId></ArticleIdList></Reference><Reference><Citation>Canetti M., Barda N., Gilboa M., Indenbaum V., Asraf K., Gonen T., Weiss-Ottolenghi Y., Amit S., Doolman R., Mendelson E., et al. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose. N. Engl. J. Med. 2022;387:2092–2094. doi: 10.1056/NEJMc2211283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2211283</ArticleId><ArticleId IdType="pmc">PMC9730934</ArticleId><ArticleId IdType="pubmed">36351266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalupka A., Richter L., Chakeri A., El-Khatib Z., Theiler-Schwetz V., Trummer C., Krause R., Willeit P., Benka B., Ioannidis J.P.A., Pilz S. Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria. Eur. J. Clin. Invest. 2024;54 doi: 10.1111/eci.14136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.14136</ArticleId><ArticleId IdType="pmc">PMC11475503</ArticleId><ArticleId IdType="pubmed">38032853</ArticleId></ArticleIdList></Reference><Reference><Citation>Porru S., Monaco M.G.L., Spiteri G., Carta A., Caliskan G., Violán C., Torán-Monserrat P., Vimercati L., Tafuri S., Boffetta P., et al. Incidence and Determinants of Symptomatic and Asymptomatic SARS-CoV-2 Breakthrough Infections After Booster Dose in a Large European Multicentric Cohort of Health Workers-ORCHESTRA Project. J. Epidemiol. Glob. Health. 2023;13:577–588. doi: 10.1007/s44197-023-00139-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44197-023-00139-8</ArticleId><ArticleId IdType="pmc">PMC10468456</ArticleId><ArticleId IdType="pubmed">37480426</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivaldi G., Jolliffe D.A., Holt H., Tydeman F., Talaei M., Davies G.A., Lyons R.A., Griffiths C.J., Kee F., Sheikh A., et al. Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK) Lancet Reg. Health. Eur. 2022;22 doi: 10.1016/j.lanepe.2022.100501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100501</ArticleId><ArticleId IdType="pmc">PMC9499825</ArticleId><ArticleId IdType="pubmed">36168404</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M., Aveyard P., Lindson N., Hartmann-Boyce J., Watkinson P., Young D., Coupland C., Clift A.K., Harrison D., Gould D., et al. Association between smoking, e-cigarette use and severe COVID-19: a cohort study. Int. J. Epidemiol. 2022;51:1062–1072. doi: 10.1093/ije/dyac028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac028</ArticleId><ArticleId IdType="pmc">PMC8903448</ArticleId><ArticleId IdType="pubmed">35179598</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>van Westen-Lagerweij N.A., Meijer E., Meeuwsen E.G., Chavannes N.H., Willemsen M.C., Croes E.A. Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth. NPJ Prim. Care Respir. Med. 2021;31:10. doi: 10.1038/s41533-021-00223-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41533-021-00223-1</ArticleId><ArticleId IdType="pmc">PMC7910565</ArticleId><ArticleId IdType="pubmed">33637750</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith G.J., Morris T.T., Tudball M.J., Herbert A., Mancano G., Pike L., Sharp G.C., Sterne J., Palmer T.M., Davey Smith G., et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat. Commun. 2020;11:5749. doi: 10.1038/s41467-020-19478-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19478-2</ArticleId><ArticleId IdType="pmc">PMC7665028</ArticleId><ArticleId IdType="pubmed">33184277</ArticleId></ArticleIdList></Reference><Reference><Citation>Clift A.K., von Ende A., Tan P.S., Sallis H.M., Lindson N., Coupland C.A.C., Munafò M.R., Aveyard P., Hippisley-Cox J., Hopewell J.C. Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort. Thorax. 2022;77:65–73. doi: 10.1136/thoraxjnl-2021-217080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-217080</ArticleId><ArticleId IdType="pmc">PMC8483921</ArticleId><ArticleId IdType="pubmed">34580193</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  EMA recommends first COVID-19 vaccine for authorisation in the EU. 2020. https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu</Citation></Reference><Reference><Citation>data.gv.at - Open Data Österreich  COVID-19: Zeitliche Darstellung von Daten zu Covid19-Fällen je Bezirk. 2020. https://www.data.gv.at/katalog/dataset/covid-19-zeitliche-darstellung-von-daten-zu-covid19-fallen-je-bezirk</Citation></Reference><Reference><Citation>Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-8-16</ArticleId><ArticleId IdType="pmc">PMC1920534</ArticleId><ArticleId IdType="pubmed">17555582</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahav D., Yelin D., Eckerle I., Eberhardt C.S., Wang J., Cao B., Kaiser L. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin. Microbiol. Infect. 2021;27:315–318. doi: 10.1016/j.cmi.2020.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.11.028</ArticleId><ArticleId IdType="pmc">PMC7718119</ArticleId><ArticleId IdType="pubmed">33285276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>